CD8A and neoplasm: Furthermore, while the impact of HMP1G NPs treatment on the frequency of CD3+CD8+ CTLs in the spleen and tumor was minor, slightly higher than the frequencies in the other treatment groups (3–4%) (Figure 6E,G), it may have led to a significant increase in specific types of CTLs infiltrating the tumor.